Trump Orders Marijuana Overhaul—Bureaucrats Stall

The same federal bureaucracy that spent decades treating marijuana like heroin is now being ordered—again—to rewrite the rules, and the White House says it’s still being “slow-walked.”

Story Snapshot

The Trump administration is pressing to reclassify marijuana from Schedule I to Schedule III, a major shift under the Controlled Substances Act.
The Justice Department is expected to finalize the rescheduling as soon as mid-April 2026, but timing remains uncertain.
The move would not legalize marijuana federally, but it could reshape taxes, research access, and compliance for state-legal businesses.
The White House is also convening enforcement-policy meetings on hemp-derived CBD and THC products as agencies weigh new guidance.

What the administration is trying to change—and why it matters

The Trump White House is pushing federal agencies to move marijuana from Schedule I to Schedule III, shifting cannabis out of the government’s most restrictive category. Schedule I status treats marijuana as having no accepted medical use and a high abuse potential, placing it alongside drugs like heroin and LSD. Schedule III, by contrast, is reserved for drugs with accepted medical uses and lower abuse potential, which could significantly change federal handling of cannabis-related research and regulation.

President Trump’s timeline traces back to a 2023 recommendation from the Department of Health and Human Services to the Drug Enforcement Administration. In December 2025, Trump signed an executive order directing the rescheduling effort and calling for faster medical research. By April 2026, reporting indicates the Justice Department could finalize the reclassification as soon as mid-month, though the exact date has not been confirmed and remains a key uncertainty.

Rescheduling is not legalization, but it could change taxes and research

Rescheduling would leave federal controls in place, meaning it would not create nationwide legal marijuana sales. Even so, the practical consequences could be substantial. One immediate impact is tax policy: state-licensed cannabis businesses have faced the limits of IRS code 280E, which can block normal business deductions for companies trafficking in Schedule I substances. If marijuana moves to Schedule III, those businesses could become eligible for deductions that reduce operating costs.

Researchers also stand to gain from a Schedule III framework. Current Schedule I rules have limited clinical research by adding red tape and narrowing pathways for lawful study. Moving marijuana into Schedule III is expected to reduce barriers to scientific work on medical applications, potentially expanding the evidence base that policymakers, regulators, and doctors rely on. That research angle is central to the administration’s stated focus, which emphasizes rescheduling rather than broad legalization.

CBD enforcement guidance is becoming the next battleground

The rescheduling push is unfolding alongside a second, more technical fight: how the federal government will enforce rules around hemp-derived CBD and THC products. The White House has begun meetings with cannabis industry and research stakeholders to discuss enforcement policy, while agencies such as the FDA and CMS work on regulatory frameworks. The Office of Information and Regulatory Affairs is involved in coordinating policy discussions, reflecting how many agencies have overlapping responsibilities in the cannabinoid market.

Opposition, lawsuits, and the “deep state” frustration both sides recognize

Not everyone wants the administration’s approach to go forward. Anti-cannabis advocacy groups, including Smart Approaches to Marijuana, are seeking in federal court to block parts of the White House’s CBD-related health care coverage initiative. Separately, at least one industry executive has questioned whether CMS has clear legal footing to move ahead quickly on coverage pathways while the FDA’s broader rules remain unsettled. Those disputes highlight how quickly federal actions can trigger litigation and procedural hurdles.

Politically, the episode also puts a spotlight on a complaint many voters—right, left, and center—share: federal agencies can stall policy even when elected leadership says “move.” Trump has publicly expressed frustration with the pace, saying officials are “slow walking” rescheduling and urging them to “get the rescheduling done.” For conservatives who want accountable government and clearer rules, the biggest test may be whether Washington can deliver transparent, lawful implementation rather than another years-long maze.